Novamind to Present at Benzinga Biotech Conference
(firmenpresse) - Panel discussion on psychedelic treatments and therapies to feature Novaminds Chief Medical Officer
TORONTO, ON / March 22, 2021 / Novamind Inc. (CSE: NM | OTC PINK: NVMDF | FSE: HN2) (Novamind or the Company), a leading mental health company specialized in psychedelic medicine, is pleased to announce its participation in the Benzinga Biotech Small Cap Conference (the Conference), a virtual conference taking place on March 25th, 2021.
On Thursday, March 25th, at 9:25am EST, Novaminds CEO and Director, Yaron Conforti, will present the Companys vision for scaling access to psychedelic medicine.
Novaminds mental health clinics and contract research businesses have been operating with psychedelic medicine since 2016, and both businesses are currently experiencing significant growth, stated Yaron Conforti, CEO and Director of Novamind. Our recently announced agreement to act as a key clinical trial site for Merck is one of many developments were excited to share with investors.
The Conference will also host a panel discussion on the use of psychedelic therapies with industry leaders including Novaminds Chief Medical Officer, Dr. Reid Robison on Thursday, March 25th at 1:10pm EST.
For more information about the conference, please click here.
About Novamind
Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca.
Contact Information
Novamind
Yaron Conforti, CEO and Director
Telephone: +1 (647) 953 9512
Bill Mitoulas, Investor Relations
Email: bill(at)novamind.ca
Forward-Looking Statements
This news release contains forward-looking statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Companys expectations including the risks detailed from time to time in the Companys public disclosure. The reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable laws.
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
" alt="Uranium Energy Corp Completes Financing to Expand Physical Uranium Initiative">
" alt="Soldera Mining Signs Share Purchase Agreement to Acquire AmTek Inc.">
Datum: 22.03.2021 - 08:30 Uhr
Sprache: Deutsch
News-ID 1565860
Anzahl Zeichen: 8475
contact information:
Contact person:
Town:
Wien
Phone:
Kategorie:
Business News
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 278 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Novamind to Present at Benzinga Biotech Conference
"
steht unter der journalistisch-redaktionellen Verantwortung von
Novamind Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
